Last reviewed · How we verify

NCT04728971

To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

Status unknown Phase 4 Last updated 16 August 2022
What this trial tests

Phase 4 trial testing Micafungin Sodium 50 MG Injection in Liver Transplantation in 200 participants. Status unknown.

Timeline
1 October 2022
Primary endpoint
1 October 2025
1 February 2026

Quick facts

Lead sponsorShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment200
Start date1 October 2022
Primary completion1 October 2025
Estimated completion1 February 2026

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Who can join

Adults 60 to 65, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the clinical success rate of micafungin in preventing invasive mycosis after liver transplantation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Transplantation

Currently open trials in the same condition.

Other Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04728971.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing